MERGE
30.4.2024 10:01:35 CEST | Business Wire | Press release
Merge, which provides unified APIs for B2B SaaS organizations to easily add hundreds of integrations to their products, has officially expanded to Europe with the establishment of its Berlin-based team. The expansion reinforces Merge’s commitment to serving European customers’ integration wants and needs effectively.
Data protection has been a top priority for European organizations since The General Data Protection Regulation (GDPR) took effect in 2018. As a result, Merge remains steadfast in prioritizing investments in security, product infrastructure, and support to assist European companies with their product integration needs.
To ensure the highest standards of security and compliance, Merge maintains ISO 27001 and SOC 2 Type 2 certifications. Additionally, Merge puts in place Data Processing Agreements (DPAs) with all customers, committing to processing data transfers in accordance with GDPR’s Standard Contractual Clauses. Furthermore, Merge supports both multi-tenant and single-tenant environments, enabling customers to fully control where their end-user data is stored.
“We know how important it is for our European customers to securely and quickly offer customer-facing integrations, which is why we’ve prioritized building and enhancing our infrastructure, security-focused features, and Europe-based software integrations,” said Shensi Ding, co-founder and CEO of Merge. “With our new team based in Berlin, we have even faster, dedicated support, providing our customers everything they need to securely and confidently use Merge.”
Merge is proud to be trusted by hundreds of Europe-based companies, including Eloomi, Payhawk, Staffbase, Hofy, TravelPerk, Ledgy, and Causal. Today, 30% of Merge’s customers are based in Europe, and these investments are aimed at better serving this market. Currently offering 200+ global integrations, Merge is focused on adding European providers as it continues to scale.
"Ledgy is being used by organizations in 45+ countries, and Merge has helped us along the way,” said Armon Bättig, head of sales at Zürich-based Ledgy - an equity management platform that uses Merge to power its HRIS integrations.
To learn more about Merge’s integrations for GDPR-compliant companies, visit: www.merge.dev/eu
European companies can visit the Merge booth at Pendomonium’s Mind the Product in London on June 20th, Berlin on June 27th, and at SaaStock in Dublin on October 14th.
About Merge:
Merge is a product integration platform that offers a suite of unified APIs to empower B2B SaaS organizations to seamlessly add hundreds of integrations to their apps. Merge’s platform makes secure data access easy by offering unified APIs across key software categories, including HRIS, accounting, CRM, file storage, and more. By handling the full integration lifecycle, Merge empowers companies to close deals faster, reduce customer churn, and save engineering costs.
Merge is backed by Accel Partners, New Enterprise Associates (NEA), and Addition, and has received $75 million in funding. Merge was founded in 2020 by Shensi Ding and Gil Feig and has offices in San Francisco, New York City and Berlin. For more information, visit Merge's website and follow the company on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430162409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom